- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Shimadzu expands mammography efforts
Shimadzu Medical Systems officially moved into the global mammography market at the RSNA show when it signed a nonexclusive distribution and marketing agreement with Planmed. According to terms of the deal, Wood Dale, IL-based Planmed’s Sophie and
Shimadzu Medical Systems officially moved into the global mammography market at the RSNA show when it signed a nonexclusive distribution and marketing agreement with Planmed. According to terms of the deal, Wood Dale, IL-based Planmeds Sophie and Sophie Classic product line will be sold worldwide under Shimadzus own name. The agreement expands a partnership established in 1995 between Planmed and Shimadzu Corporation, which allows Shimadzu to market Planmeds mammography products in Japan under the trade name Sepio. The new agreement extends Shimadzus distribution of Planmed mammography products to North and South America, Europe, and Australia.
The deal allows Shimadzu to fill out its product portfolio and target larger strategic accounts such as group purchasing and veterans organizations and hospital networks, according to Don Karle, director of sales and marketing for North America. The Torrance, CA-based firm plans to sell between 30 and 50 mammography units in 2000, Karle said.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
